Tech Company Financing Transactions
Escient Pharmaceuticals Funding Round
Escient Pharmaceuticals closed a $40 million Series A funding round on 5/10/2018. Backers included 5AM Ventures, Osage Partners and The Column Group.
Transaction Overview
Company Name
Announced On
5/10/2018
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Proceeds Purpose
cing, syndicated by The Column Group and 5AM Ventures and joined by Osage University Partners, to build out its team, advance its pipeline, and progress its initial preclinical programs to clinical study.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10578 Science Center Dr. 250
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Escient Pharmaceuticals. We are a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alain Baron
Chief Scientific Officer
Marcus Boehm
Vice President
Richard Pittner
Vice President
Kristin Taylor
Vice President
Gregg Timony
VP - Bus. Development
William Hodder
VP - R & D
Esther Martinborough
Browse more venture capital transactions:
Prev: 5/10/2018: ClickFox venture capital transaction
Next: 5/10/2018: At-Bay venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs